Author:
Lin Che-Liang,Chen Shou-Chien,Liu Shyun-Yeu,Chen Kow-Tong
Abstract
Although rotavirus vaccines are available, rotaviruses remain the major cause of childhood diarrheal disease worldwide. The Rotarix (GlaxoSmithKline Biologicals Rixensart, Belgium) and RotaTeq (Merck and Co., Inc. Whitehouse Station, New Jersey, USA) vaccines are effective for reducing the morbidity and mortality of rotavirus infection. This article aims to assess the epidemiology of rotaviral gastroenteritis and the efficacy and effectiveness of licensed rotavirus vaccines. This review concludes by presenting challenges in the field that require further exploration by and perspectives from basic and translational research in the future.
Publisher
Bentham Science Publishers Ltd.
Reference76 articles.
1. Estes MK, Kapikian AZ, Eds.
Rotaviruses.
In nipe Fields virology. 5th ed..
Philadelphia (PA): Lippincott, Williams and Wilkins, 2007.
2. Bishop RF, Davidson GP, Holmes IH , et al.
Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis.
Lancet
1973;
2
: 1281-3.
3. Desselberger U.
Rotaviruses.
Virus Res
2014;
190C
: 75-96.
4. Hoshino Y, Kapikian AZ.
Rotavirus serotypes classification and importance in epidemiology, immunity and vaccine development.
J Health Popul Nutr
2000;
18
: 5-14.
5. Gentsch Jr, Laird AR, Bielfelt B , et al.
Serotype diversity and reassortment between human and animal rotavirus strains implications for rotavirus vaccine programs.
J Infect Dis
2005;
192
: S146-59.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献